Literature DB >> 6765970

Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation.

S Livnat, M Seigneuret, R Storb, R L Prentice.   

Abstract

Cytotoxic effector cells mediating natural killing (NK), antibody-dependent cellular cytotoxicity (ADCC), and lectin-dependent cellular cytotoxicity (LDCC) were studied in patients with leukemia or aplastic anemia before and/or after marrow transplantation. Before transplantation, about one-third to one-half of the patients were deficient in cytotoxic activity. In patients with leukemia, this was most likely due to large numbers of circulating blast cells diluting or replacing the effector cells. In patients with aplastic anemia there was an apparent absence of the effector cells in a proportion of the patients. After marrow transplantation, cytotoxic activity in all three systems returned to normal rapidly, by 30 days, and remained so through 100 days. However, about 20% of patients studied beyond 1 year were deficient in these functions. There were no significant associations between cytotoxic activity and important clinical parameters including infections, graft-vs-host disease, and recurrence of leukemia. Our findings do not support an immunosurveillance role for NK against leukemia after marrow transplantation. Furthermore, they point out the need for new in vitro approaches for meaningful monitoring of marrow transplant patients. Finally, our results showed a significant discordance between NK, ADCC, and LDCC activities in these immunologically perturbed individuals, indicating that either different cell populations or different cellular mechanisms are involved in these cytotoxic functions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6765970

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Graft versus leukemia in bone marrow transplantation.

Authors:  M Boranić
Journal:  Blut       Date:  1988-08

2.  Functional analysis of CD8 lymphocytes in long-term surviving patients after bone marrow transplantation.

Authors:  M Divine; J P Lecouedic; M F Gourdin; N Oudhriri; M Zohair; T Henni; F Beaujan; J P Vernant; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

3.  Natural killer cell activity against a thymoma cell line Thy 121 in bone marrow transplant recipients.

Authors:  E Heidemann; H Schmidt; K Schüch; P Ostendorf; H D Waller
Journal:  Klin Wochenschr       Date:  1986-02-03

4.  T-lymphocyte subpopulations in the peripheral blood and bone marrow of patients with aplastic anemia.

Authors:  R P Falcão; J C Voltarelli; C Bottura
Journal:  Blut       Date:  1985-02

Review 5.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 6.  Natural killer cells: artifact to reality: an odyssey in biology.

Authors:  R K Oldham
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 7.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

8.  Immune status of Greek patients with beta-thalassemia major negative for anti-HIV.

Authors:  H Choremi; E Sidiri; K Psarra; J Economidou; P Georgiopoulou; C Politi; A Roumeliotou; G Papaevangelou
Journal:  Blut       Date:  1987-05

9.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

10.  What is the role for donor natural killer cells after nonmyeloablative conditioning?

Authors:  Frédéric Baron; Effie W Petersdorf; Ted Gooley; Brenda M Sandmaier; Mari Malkki; Thomas R Chauncey; David G Maloney; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2009-05       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.